H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
Lexicon Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
Strategic Partnership and Financial Incentives Drive Buy Rating for Lexicon Pharmaceuticals
Piper Sandler Reaffirms Their Buy Rating on Lexicon Pharmaceuticals (LXRX)
Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
Lexicon Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
Buy Rating Affirmed for Lexicon Pharmaceuticals Based on Sotagliflozin's Market Potential and Favorable Safety Data
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Travere Therapeutics (TVTX)
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
Buy Rating Affirmed for Lexicon Pharmaceuticals on Promising INPEFA Heart Failure Treatment Data
Lexicon Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
Buy Rating for Lexicon Pharmaceuticals Amid Positive Regulatory and Clinical Developments for ZYNQUISTA
Lexicon Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10